gms | German Medical Science

Deutscher Rheumatologiekongress 2024

52. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
34. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)
38. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)

18.09. - 21.09.2024, Düsseldorf

Transcriptome analysis shows immunological plasticity and heterogeneity in pustular psoriasis (GPP, PPP) – new opportunities for personalized therapy

Meeting Abstract

  • Esther Tiessen - Universitätsklinikum Ulm, ZPMi/Klinik für Dermatologie und Allergologie, Ulm
  • Pallab Maity - Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm
  • Veronika Hall - Universitätsklinikum Ulm, ZPMi/Klinik für Dermatologie und Allergologie, Ulm
  • Lilly Maile - Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm
  • Karin Scharffetter-Kochanek - Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm
  • Johannes Martin Weiss - Universitätsklinikum Ulm, ZPMi/Klinik für Dermatologie und Allergologie, Ulm

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2024, 52. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immmunologie (DGRh), 34. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 38. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh). Düsseldorf, 18.-21.09.2024. Düsseldorf: German Medical Science GMS Publishing House; 2024. DocET.20

doi: 10.3205/24dgrh028, urn:nbn:de:0183-24dgrh0284

Veröffentlicht: 18. September 2024

© 2024 Tiessen et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Psoriasis is a major risk factor regarding the development of spondyloarthritis. The most common type is Psoriasis vulgaris which is understood to be driven mainly by increased Interleukin (IL) 23 and 17 levels. However, there are rare, pustular forms of psoriasis in which neutrophils play a dominant role: The potentially life-threatening Generalized pustular psoriasis (GPP), Palmoplantar psoriasis (PPP) and Acrodermatitis continua suppurativa Hallopeau (ACH) which merely affects fingers and toes.

Treatment of these conditions with the established psoriasis armamentarium of immunomodulating therapies is more or less a trial-and-error game because pathophysiology of these entities has not been decoded properly yet.

Methods: Focusing on differential transcriptomic differences in GPP vs. PPP bulk RNA sequencing of affected skin and healthy skin of 3 GPP and 3 PPP patients was performed and results were compared to each other and to matching healthy skin samples.

Results: PCA (Principal Component Analysis) showed 3 distinct clusters of differential gene expression profiles (lesional GPP, lesional PPP and unaffected skin). Detailed analysis of heatmaps confirmed the expected up-regulation of IL 17, IL 23 and IL 36 pathway related genes, especially in GPP. The latter has been highlighted recently in the pivotal study of Spesolimab (anti–IL-36R mAb) indicated for acute flares of GPP. Surprisingly, IL 1 signaling in PPP was lower than in healthy controls. In PPP-patients the above immune signatures, although differentially regulated, struck with a notable heterogeneity. Unexpectedly, in GPP a marked atopic milieu with an upregulated Th2 profile was detected.

Conclusion: From a translational point of view these findings explain the unsatisfying results of classical psoriasis bDMARD therapies in pustular psoriasis.

As the number of patients of this study is small further research is required to get clearer insights of pustular psoriasis to make personalized medicine in clinical immunology more likely.


References

1.
Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022 Oct;18(10):1033-47. DOI: 10.1080/1744666X.2022.2116003 Externer Link
2.
Baum P, Visvanathan S, Garcet S, Roy J, Schmid R, Bossert S, Lang B, Bachelez H, Bissonnette R, Thoma C, Krueger JG. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022 Apr;149(4):1402-12. DOI: 10.1016/j.jaci.2021.09.035 Externer Link
3.
Bissonnette R, Fuentes-Duculan J, Mashiko S, Li X, Bonifacio KM, Cueto I, Suárez-Fariñas M, Maari C, Bolduc C, Nigen S, Sarfati M, Krueger JG. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017 Jan;85(1):20-6. DOI: 10.1016/j.jdermsci.2016.09.019 Externer Link
4.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022 Jan;23(Suppl 1):13-9. DOI: 10.1007/s40257-021-00655-y Externer Link
5.
McCluskey D, Benzian-Olsson N, Mahil SK, Hassi NK, Wohnhaas CT; APRICOT and PLUM study team; Burden AD, Griffiths CEM, Ingram JR, Levell NJ, Parslew R, Pink AE, Reynolds NJ, Warren RB, Visvanathan S, Baum P, Barker JN, Smith CH, Capon F. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022 Oct;150(4):882-93. DOI: 10.1016/j.jaci.2022.04.027 Externer Link